Magazine Article | March 1, 2019

Companies To Watch: Azitra

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Azitra is a small, young, early-stage company developing microbial biotherapeutics for conditions arising on the skin that can be addressed by using the microbiome. The products are in three categories: consumer products containing proprietary microbe strains, pharmaceuticals using microbes to produce and deliver therapeutic proteins to the skin, and “novel bioactive compounds” derived by genetic engineering of commensal microbes. At this point, the company has a pipeline of four candidates, almost all still at the discovery or preclinical stages, for treating a range of skin conditions: eczema and ichthyosis vulgaris, Netherton syndrome, inflammatory disease in psoriasis, rashes associated with cancer treatment, and cosmetic use (rough, dry skin). The first cosmetic clinical study began in January 2019.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader